Whole brain radiation versus stereotactic radiation in patients with 5-20 brain metastases: A phase III, randomized clinical trial

This research study is studying two different types of radiation as treatment for brain
metastases (tumors in the brain that spread from a cancer that originated elsewhere in the
body)

Inclusion Criteria:

- Participants must have a biopsy proven solid malignancy with untreated (by radiation)
intracranial lesions radiographically consistent with or pathologically proven to be
brain metastases. Patients who have undergone prior systemic therapy are eligible

- Five-twenty intracranial lesions must be present on MRI of the brain

- Age 18-80 years at diagnosis of brain metastases

- Karnofsky performance status of at least 70

Exclusion Criteria:

- Participants who have undergone prior radiation for brain metastases.

- Patients who have undergone resection of one or more brain metastases but who have not
yet started adjuvant radiotherapy are eligible for the study

- Participants who cannot undergo a brain MRI

- Participants who cannot receive gadolinium (MRI contrast)

- Participants with stage IV-V chronic kidney disease or end stage renal disease

- Participants with widespread, definitive leptomeningeal disease

- Participants with small cell lung cancer, lymphoma, or myeloma

- Participants with a maximum tumor diameter exceeding 5 cm (if not resected)